Chlamydia Infection Treatment Market
Chlamydia Infection is defined as sexually transmitted infection caused by bacteria known as chlamydia trachomatis. Chlamydia Infection may not cause symptoms. It spread via vaginal, anal, and oral sex. The infection is carried in semen and vaginal fluids. It can infect the penis, vagina, cervix, anus, eyes, urethra, and throat. The infection affects people of all ages but is most common in young women.
Market Drivers
The increase in prevalence of sexually transmitted diseases which expected to boost the growth of global chlamydia infection treatment market over the forecast period. For instance, as per the information provided by the Centers for Disease Control and Prevention (CDC), in year 2016, around 1,598,354 cases of Chlamydia trachomatis infection were reported in the United States. Also, the increase in awareness among the population for sexually transmitted diseases as well as the increase in government initiatives to spread awareness for sexually transmitted diseases will positively influence the market growth. For instance, as per the Centers for Disease Control and Prevention (CDC), the chlamydial infection has the highest prevalence in people aged ≤24 years in the United States.
A significant proportion of sexually transmitted diseases (STDs) across the globe is caused by eight major infections such as chlamydia, syphilis, gonorrhea, genital herpes, hepatitis B, human papillomavirus and trichomoniasis. These diseases have a high prevalence, particularly in developing nations, and it can result in substantial productivity losses for individuals & communities.
Market Restraints
Low rate of screening for diseases and late diagnosis of the diseases is the major restraining factor which expected to hamper the growth of global chlamydia infection treatment market during this forecast period. Also, limited access to sexually transmitted disease diagnosis in developing nations may hinder the market growth.
Market segmentation
The Chlamydia Infection Treatment Market is segmented into test type Culture Tests, Nucleic Acid Amplification Test (NAAT), Direct Fluorescent Antibody Test, Serology Tests, and Others. By Causative Organisms such as Chlamydia trachomatis, and Chlamydophila pneumoniae. Further, market is segmented into end user such as Hospitals, Diagnostic Centers, and Others.
Regional Analysis
The Chlamydia Infection Treatment Market is segmented into five regions such as North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.
North America region is expected to dominate the Chlamydia Infection Treatment Market, due to the well-established healthcare system, growing adoption rate of medical screening, and presence of a high number of pharmaceutical and biopharmaceutical companies. Also, the high prevalence of sexually transmitted diseases in the region. Moreover, the presence of major key players in the region and their contribution through merger and acquisition and product launch is also contributing the market growth.
Key Players
Various key players are listed in this report such as Merck & Co. Inc, Novartis, Eli Lilly and Company, Sun Pharma, Teva Pharmaceuticals, Sanofi, Gilead Sciences Inc., AstraZeneca, GlaxoSmithKline Plc, Pfizer Inc, etc.
Market Taxonomy
By Test Type
By Causative Organism
By End User
By Region
Key Questions Addressed by the Report
Global Chlamydia Infection Treatment Market TOC
1 Introduction
1.1 Objective of the Study
1.2 Market definition
1.3 Market Scope
2 Research Methodology
2.1 Data Mining
2.2 Validation
2.3 Primary Interviews
2.4 List of Data Sources
3 Executive Summary
4 Global Chlamydia Infection Treatment Market Outlook
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
5 Global Chlamydia Infection Treatment Market, By Test Type
5.1 Y-o-Y Growth Comparison, By Test Type
5.2 Global Chlamydia Infection Treatment Market Share Analysis, By Test Type
5.3 Global Chlamydia Infection Treatment Market Size and Forecast, By Test Type
5.3.1 Culture Tests
5.3.2. Nucleic Acid Amplification Test (NAAT)
5.3.3. Direct Fluorescent Antibody Test
5.3.4. Serology Tests
5.3.5.Others
6 Global Chlamydia Infection Treatment Market, By Causative Organism
6.1 Y-o-Y Growth Comparison, By Causative Organism
6.2 Global Chlamydia Infection Treatment Market Share Analysis, By Causative Organism
6.3 Global Chlamydia Infection Treatment Market Size and Forecast, By Causative Organism
6.3.1 Chlamydia trachomatis
6.3.2 Chlamydophila pneumoniae
7 Global Chlamydia Infection Treatment Market, By End User
7.1 Y-o-Y Growth Comparison, By End User
7.2 Global Chlamydia Infection Treatment Market Share Analysis, By End User
7.3 Global Chlamydia Infection Treatment Market Size and Forecast, By End User
7.3. 1 Hospitals
7.3.2. Diagnostic Centers
7.3.3. Others
8Global Chlamydia Infection Treatment Market, By Region
8.1 Global Chlamydia Infection Treatment Market Share Analysis, By Region
8.2 Global Chlamydia Infection Treatment Market Share Analysis, By Region
8.3 Global Chlamydia Infection Treatment Market Size and Forecast, By Region
9 North America Chlamydia Infection Treatment Market Analysis and Forecast (2020-2030)
9.1 Introduction
9.2 North America Chlamydia Infection Treatment Market Share Analysis, By Test Type
9.3 North America Chlamydia Infection Treatment Market Size and Forecast, By Causative Organism
9.4 North America Chlamydia Infection Treatment Market Size and Forecast, By End User
9.5 North America Chlamydia Infection Treatment Market Size and Forecast, By Country
9.5.1 U.S.
9.5.2 Canada
9.5.3 Mexico
10EuropeChlamydia Infection Treatment Market Analysis and Forecast (2020-2030)
10.1 Introduction
10.2 Europe Chlamydia Infection Treatment Market Share Analysis, By Test Type
10.3 Europe Chlamydia Infection Treatment Market Size and Forecast, By Causative Organism
10.4 Europe Chlamydia Infection Treatment Market Size and Forecast, By End User
10.5 Europe Chlamydia Infection Treatment Market Size and Forecast, By Country
10.5.1 Germany
10.5.2 France
10.5.3 UK
10.54. Rest of Europe
11Asia Pacific Chlamydia Infection Treatment Market Analysis and Forecast (2020-2030)
11.1 Introduction
11.2 Asia Pacific Chlamydia Infection Treatment Market Share Analysis, By Test Type
11.3 Asia Pacific Chlamydia Infection Treatment Market Size and Forecast, By Causative Organism
11.4 Asia Pacific Chlamydia Infection Treatment Market Size and Forecast, By End User
11.5 Asia Pacific Chlamydia Infection Treatment Market Size and Forecast, By Country
11.5.1 China
11.5.2 Japan
11.5.3 India
11.5.4. Rest of Asia Pacific
12Latin America Chlamydia Infection Treatment Market Analysis and Forecast (2020-2030)
12.1 Introduction
12.2 Latin America Chlamydia Infection Treatment Market Share Analysis, By Test Type
12.3 Latin America Chlamydia Infection Treatment Market Size and Forecast, By Causative Organism
12.4 Latin America Chlamydia Infection Treatment Market Size and Forecast, By End User
12.5 Latin America Chlamydia Infection Treatment Market Size and Forecast, Country
13Middle East Chlamydia Infection Treatment Market Analysis and Forecast (2020-2030)
13.1 Introduction
13.2 Middle East Chlamydia Infection Treatment Market Share Analysis, By Test Type
13.3 Middle East Chlamydia Infection Treatment Market Size and Forecast, By Causative Organism
13.4 Middle East Chlamydia Infection Treatment Market Size and Forecast, By End User
13.5 Middle East Chlamydia Infection Treatment Market Size and Forecast, By Country
14Competitive Analysis
14.1 Competition Dashboard
14.2 Market share Analysis of Top Vendors
14.3 Key Development Strategies
15Company Profiles
15.1 Merck & Co. Inc
15.1.1 Overview
15.1.2 Offerings
15.1.3 Key Financials
15.1.4 Business Segment & Geographic Overview
15.1.5 Key Market Developments
15.1.6 Key Strategies
15.2. Novartis
15.2.1 Overview
15.2.2 Offerings
15.2.3 Key Financials
15.2.4 Business Segment & Geographic Overview
15.2.5 Key Market Developments
15.2.6 Key Strategies
15.3. Eli Lilly and Company
15.3.1 Overview
15.3.2 Offerings
15.3.3 Key Financials
15.3.4 Business Segment & Geographic Overview
15.3.5 Key Market Developments
15.3.6 Key Strategies
15.4 Sun Pharma
15.4.1 Overview
15.4.2 Offerings
15.4.3 Key Financials
15.4.4 Business Segment & Geographic Overview
15.4.5 Key Market Developments
15.4.6 Key Strategies
15.5 Teva Pharmaceuticals
15.5.1 Overview
15.5.2 Offerings
15.5.3 Key Financials
15.5.4 Business Segment & Geographic Overview
15.5.5 Key Market Developments
15.5.6 Key Strategies
15.6 Sanofi
15.6.1 Overview
15.6.2 Offerings
15.6.3 Key Financials
15.6.4 Business Segment & Geographic Overview
15.6.5 Key Market Developments
15.6.6 Key Strategies
15.7 Gilead Sciences Inc
15.7.1 Overview
15.7.2 Offerings
15.7.3 Key Financials
15.7.4 Business Segment & Geographic Overview
15.7.5 Key Market Developments
15.7.6 Key Strategies
15.8 AstraZeneca
15.8.1 Overview
15.8.2 Offerings
15.8.3 Key Financials
15.8.4 Business Segment & Geographic Overview
15.8.5 Key Market Developments
15.8.6 Key Strategies
15.9 GlaxoSmithKline Plc
15.9.1 Overview
15.9.2 Offerings
15.9.3 Key Financials
15.9.4 Business Segment & Geographic Overview
15.9.5 Key Market Developments
15.9.6 Key Strategies
15.10 Pfizer Inc
15.10.1 Overview
15.10.2 Offerings
15.10.3 Key Financials
15.10.4 Business Segment & Geographic Overview
15.10.5 Key Market Developments
15.10.6 Key Strategies
